Autonomix Medical (Nasdaq:AMIX) announced that it received a new patent titled controlled sympathectomy and micro-ablation systems and methods.
U.S. Patent No. 12,257,071 (‘071 patent) relates to advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation. The technologies provide enhanced precision in treating nerve-related conditions.
The Woodlands, Texas-based Autonomix said its systems enable the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. Its new patent marks a step forward in the company’s mission, according to a news release. It wants to deliver more effective, less invasive treatments for neurological conditions like chronic pain, hypertension and more.
Autonomix said its patent covers features of the technology such as deployable microfingers with embedded sensors for real-time monitoring. It also extends to the ability to map, stimulate, ablate and assess nerve activity in a single integrated system. Additionally, the patent covers feedback-driven control for multiple types of procedures and supports adaptive modulation.
Autonomix designed its technology for renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders. It utilizes a catheter-based microchip sensing array antenna. This could detect and differentiate neural signals with greater sensitivity than currently available technologies. Once the sensor identifies target nerves, proprietary RF ablation technology kills those nerves.
The company plans to submit for FDA investigational device exemption (IDE) to begin U.S. clinical trials this year.
“We are excited to announce the issuance of this patent, marking a key milestone in our strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation. This innovative technology enhances our intellectual property position in the rapidly growing nerve-focused therapeutics space, allowing us to protect our offerings and deliver improved solutions for both clinicians and patients. This patent is a vital addition to our expanding portfolio as we continue working toward our goal of revolutionizing the treatment of nerve-related conditions,” said Brad Hauser, CEO of Autonomix.
